Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0366220160510010023
Korean Journal of Hematology
2016 Volume.51 No. 1 p.23 ~ p.30
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature
Karthik Bommannan

Man Updesh Singh Sachdeva
Pankaj Malhotra
Narender Kumar
Prashant Sharma
Shano Naseem
Jasmina Ahluwalia
Reena Das
Neelam Varma
Gaurav Prakash
Alka Khadwal
Radhika Srinivasan
Subhash Varma
Abstract
Background: Plasma cell leukemia (PCL) is a rare and aggressive plasma cell neoplasm. In PCL, clonal plasma cells comprise ¡Ã20% of the peripheral blood (PB) leukocytes and/or the absolute clonal PB plasma cell count is ¡Ã2¡¿109/L. Primary PCL (PPCL) originates de novo, whereas, secondary PCL (SPCL) evolves from pre-existing multiple myeloma.

Methods: Clinicohematological features, immunophenotypic profile, and survival of PCL patients were analyzed retrospectively.

Results: Between January 2007 and December 2014, ten PPCL and four SPCL patients were investigated (8 PPCLs and 3 SPCLs had complete clinical data). All were North Indians, sharing common geography and ethnicity. Our cohort showed less frequent renal failure, more frequent hepatomegaly, and non-secretory type disease. In contrast to western literature, flow cytometric immunophenotyping of our cohort revealed altered expression of CD138 (67%), CD56 (33%), and CD20 (0%). With novel therapeutic agents, these PPCL patients had a median overall survival of 15 months.

Conclusion: We highlight that our PPCL patients from North India had distinct clinicohematological and immunophenotypic profiles. The significance of our findings must be tested in a larger patient cohort and must be supported by molecular and cytogenetic investigations to unmask possible significant effects on pathogenesis.
KEYWORD
Clinicohematological profile, North India, Plasma cell leukemia, Immunophenotype, Survival
FullTexts / Linksout information
  
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø